Login / Signup
Robert Popp
ORCID
Publication Activity (10 Years)
Years Active: 2024-2024
Publications (10 Years): 4
Top Topics
Ejection Fraction
Protein Kinase
End Stage Renal Disease
Patient Reported Outcomes
Top Venues
Cancer research communications
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Constance A Sobsey
,
Bjoern C Froehlich
,
Georgia Mitsa
,
Sahar Ibrahim
,
Robert Popp
,
René Peiman Zahedi
,
Elza C de Bruin
,
Christoph H Borchers
,
Gerald Batist
mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors.
Cancer research communications
4 (8) (2024)
Constance A Sobsey
,
Bjoern C Froehlich
,
Georgia Mitsa
,
Sahar Ibrahim
,
Robert Popp
,
René Peiman Zahedi
,
Elza C de Bruin
,
Christoph H Borchers
,
Gerald Batist
mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors.
Cancer research communications
4 (8) (2024)
Constance A Sobsey
,
Bjoern C Froehlich
,
Georgia Mitsa
,
Sahar Ibrahim
,
Robert Popp
,
René Peiman Zahedi
,
Elza C de Bruin
,
Christoph H Borchers
,
Gerald Batist
mTORC1-driven protein translation correlates with clinical benefit of capivasertib within a genetically preselected cohort of PIK3CA-altered tumours.
Cancer research communications
(2024)
Constance A Sobsey
,
Bjoern C Froehlich
,
Georgia Mitsa
,
Sahar Ibrahim
,
Robert Popp
,
René Peiman Zahedi
,
Elza C de Bruin
,
Christoph H Borchers
,
Gerald Batist
mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors.
Cancer research communications
4 (8) (2024)